Search clinical trials for: BI 1356 BS tablet - high dose

Total 131 results

Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Denmark, France, Ireland, Korea, Republic of, Portugal, United Kingdom
Boehringer Ingelheim

Completed

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

Hepatitis C, Chronic

United States, Germany, Spain, United Kingdom
Boehringer Ingelheim

Completed

Pharmacokinetics of Single and Multiple Oral Doses of BI 1356 in Healthy Chinese Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BI 1356 BS and Metformin After Co-administration Compared to the Bioavailability of BI 1356 BS Alone and Metformin Alone in Healthy Male Volunteers

Healthy
Vaxart

Completed

Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults

Seasonal Influenza B

New Zealand
Charleston Laboratories, Inc

Completed

A Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route

Pain | Nausea | Vomiting
Sangart

Completed

Phase III Study of Hemospan® to Prevent Hypotension in Hip Arthroplasty

Ischemia | Hypotension

Netherlands, Belgium, Czech Republic, Sweden, Poland, United Kingdom
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Canada, China, France, Germany, India, Korea, Republic of, Mexico, Slovakia, Slovenia, Taiwan, Turkey
Alladapt Immunotherapeutics, Inc.

Completed

ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults

Food Allergy

United States
Forma Therapeutics, Inc.
Novo Nordisk A/S

Recruiting

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

Sickle Cell Disease

United States, Italy, Spain, United Kingdom, France, Lebanon, Germany, Oman, Canada, Greece
Boehringer Ingelheim

Completed

Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Liver Diseases | Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 653048 BS H3PO4 Capsule Multiple Rising Doses in Healthy Male Volunteers

Healthy
Prim. Priv. Doz. Dr. Daniel Cejka
Vifor Fresenius Medical Care Renal Pharma

Completed

The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum

Endstage Renal Disease

Austria
Boehringer Ingelheim

Completed

Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male Subjects

Healthy
Boehringer Ingelheim

Completed

Effects of BI 44370 TA Orally Applied as Tablets on the Pharmacokinetics of Orally Administered Midazolam Solution in Healthy Volunteers

Healthy
Shenzhen Ausa Pharmed Co.,Ltd
Peking University First Hospital; China Medical University, China; Fudan University and other collaborators

Unknown

Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine

Essential Hypertension

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Shenzhen Ausa Pharmed Co.,Ltd
Ruijin Hospital; Xuzhou Medical University; Second Affiliated Hospital of Nanchang...

Unknown

Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine

Essential Hypertension

China
Boehringer Ingelheim

Completed

4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)

Diabetes Mellitus, Type 2

Japan
China-Japan Friendship Hospital

Recruiting

The Effects of Low-Dose Versus High-Dose Intravenous IRON Therapy With Ferric DerisomaltOSE in Patients With Chronic Heart Failure and Iron Deficiency (IRONDOSE)

Heart Failure | Iron Deficiency

China
Bayer

Completed

Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects

Pharmacokinetics

Germany
Gilead Sciences

Not yet recruiting

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

HIV-1-infection
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Dr. Falk Pharma GmbH

Completed

Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis

Eosinophilic Esophagitis

Germany
Boehringer Ingelheim

Completed

The Effect of Multiple Oral Doses of BI 1356 BS on Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of Simvastatin and on the Pharmacokinetics of Its Metabolite Simvastatin Acid in Healthy Male Volunteers

Healthy
Engelhard Arzneimittel GmbH & Co.KG
ClinCompetence Cologne GmbH

Completed

Sinolpan® Pharmacy Non-interventional Study - Quality of Live

Bronchitis | Rhinosinusitis Chronic | Rhinosinusitis Acute

Germany
Vyne Therapeutics Inc.

Completed

Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis (ATOMIK)

Pruritus | Atopic Dermatitis

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Phase II Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia

Community Acquired Pneumonia

China
Boehringer Ingelheim

Completed

Investigation of Pharmacokinetic Drug-drug Interaction of BI 409306 and Donepezil in Healthy Male and Female Subjects

Healthy

Germany
Beijing Tiantan Hospital
NeuroDawn Pharmaceutical Co., Ltd.

Not yet recruiting

EFfects of Y-6 SUblingual Tablets foR PaTients With AcUte Ischemic StRokE (FUTURE)

Acute Ischemic Stroke | Large Vessel Occlusion | Reperfusion
Daiichi Sankyo, Inc.
The TIMI Study Group

Completed

Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation (EngageAFTIMI48)

Stroke | Embolism | Atrial Fibrillation

United States, Australia, France, Italy, Poland, Taiwan, Ukraine, United Kingdom, China, Belgium, Germany, Spain, Argentina, Colombia, Israel, Mexico, Portugal, Bulgaria, India, Romania, Russian Federation, Serbia, South Africa, Turkey, Korea, Republic of and more
Stanford University
Santen Inc.

Withdrawn

Intravitreal Sirolimus as Therapeutic Approach to Uveitis (SAVE-2)

Panuveitis | Uveitis | Posterior Uveitis | Intermediate Uveitis

United States
Alan Barkun
Pendopharm

Completed

The Bowel CLEAnsing: A National Initiative (B-CLEAN)

Subjets Requiring a Colonoscopy

Canada
Boehringer Ingelheim

Completed

Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, Compared to Metoprolol Succinate and Placebo in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetic Interaction Between Tipranavir and BILR 355 BS Plus Ritonavir in Healthy Male Volunteers

Healthy
Velicept Therapeutics, Inc.

Completed

Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women

Overactive Bladder

United States
Sun Yat-sen University

Unknown

The Intervention of Multi-vitamin With Minerals to Hyperuricemia

Hyperuricemia

China
Velicept Therapeutics, Inc.

Completed

A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001) (VEL-2001)

Overactive Bladder

United States
Shanghai Jiao Tong University School of Medicine
YUNNAN BAIYAO GROUP CO.,LTD

Completed

Study of Oral High/Low-dose Cepharanthine Compared With Placebo in Non Hospitalized Adults With COVID-19

Asymptomatic COVID-19

China
Huazhong University of Science and Technology
Wuhan Union Hospital, China; Guangzhou University of Traditional Chinese Medicine and other collaborators

Unknown

Trial for Quantity-Effect Relationship of Acupuncture With Two-ways Regulation to Treat Functional Enteropathy

Functional Constipation | Functional Diarrhea

China
Boehringer Ingelheim

Completed

Effect of Repeated Doses of BI 1060469 and BI 1021958 on Glomerular Filtration Rate (GFR) in Healthy Volunteers

Healthy

Germany
BioInvent International AB

Terminated

A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma

Multiple Myeloma

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Belgium, Canada, China, Germany, India, Ireland, Japan, Switzerland
Marker Therapeutics, Inc.

Completed

Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer

Breast Cancer

United States
GlaxoSmithKline

Active, not recruiting

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

Infections, Meningococcal

United States, Australia, Finland, Poland, Belgium, Brazil, Sweden, Turkey
Tris Pharma, Inc.
Forest Laboratories

Completed

Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.

Low Back Pain

Austria, Belgium, Denmark, Finland, Germany, Hungary, Netherlands, Poland, Spain, Sweden, United Kingdom
Boehringer Ingelheim

Completed

Influence of Food on the Bioavailability of Telmisartan / Ramipril Fixed Dose Combination in Healthy Male and Female Volunteers

Healthy
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome (VAMOS)

Hypertension | Metabolic Syndrome

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Wayne State University

Completed

Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence (BOS)

Heroin Dependence | Opioid Use Disorder

United States

3

Subscribe